Fabrazyme cleared GL-3 as
quickly as 5 months in the
capillary endothelium of the
kidney, heart, and skin.1*
GL-3 and maintained
it for up to 5 years.1
*At 5 months, GL-3 clearance was observed in the capillary endothelium of the: Kidney: 20 (69%) Fabrazyme patients compared to 0 (0%) placebo patients; Heart: 21 (72%) Fabrazyme patients compared to 1 (3%) placebo patient; Skin: 29 (100%) Fabrazyme patients compared to 1 (3%) placebo patient.
Fabrazyme® (agalsidase beta) is indicated for use in patients with Fabry disease. Fabrazyme reduces globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types.
The reduction of GL-3 inclusions suggests that Fabrazyme may ameliorate disease expression; however, the relationship of GL-3 inclusion reduction to specific clinical manifestations of Fabry disease has not been established.
Fabry disease is a progressive, often life-threatening disease. Undiagnosed or unmanaged, Fabry disease can reduce life expectancy
by 15 years in women and 20 years in men.2-4 Learn more about managing Fabry disease.